ABSTRACT Immunoglobulin heavy chain variable region‐unmutated (IGHV‐U) chronic lymphocytic leukemia (CLL) represents a biologically aggressive subgroup with limited responsiveness to chemoimmunotherapy (CIT). To clarify the comparative effectiveness of available frontline options, we conducted a comprehensive Bayesian network meta‐analysis of ...
Santino Caserta +13 more
wiley +1 more source
Hairy Cell Leukemia With Aberrant CD5 and CD23 Expression: A Case Report and a Brief Literature Review. [PDF]
Alameddine Z +4 more
europepmc +1 more source
Bone Marrow Pathology in Cold Agglutinin‐Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases
ABSTRACT Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). CAD occurs in the context of a small clonal B‐cell lymphoproliferation restricted to blood and/or bone marrow (BM), without overt or extramedullary lymphoma. The WHO‐HAEM5 introduced a description of the CAD‐associated lymphoproliferative disorder (CAD‐LPD) in ...
Anne‐Marie L. Becking +6 more
wiley +1 more source
High-Risk Chronic Lymphocytic Leukemia in a Young Adult Treated With Reduced-Dosage, Fixed-Duration Ibrutinib and Venetoclax. [PDF]
Gutierrez CLD +3 more
europepmc +1 more source
ABSTRACT Adult T‐cell leukemia/lymphoma (ATL) is an aggressive hematological malignancy with a poor prognosis and limited therapeutic options. ATL cells exhibit aberrant surface glycosylation patterns resulting from dysregulated glycosyltransferase expression, representing a potentially tumor‐specific therapeutic target.
Yuichiro Uchida +7 more
wiley +1 more source
Lymphocyte count and risk of chronic lymphocytic leukemia. [PDF]
Pahnke S +6 more
europepmc +1 more source
From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino +13 more
wiley +1 more source
The Immunologic Paradox of BTK Inhibitors in Chronic Lymphocytic Leukemia: Selectivity, Hypogammaglobulinemia, and Infection Risk. [PDF]
Andreescu M +8 more
europepmc +1 more source
Regional Standardization of CLL Management: Results of a Delphi Consensus Process
ABSTRACT The therapeutic landscape of chronic lymphocytic leukemia (CLL) has been profoundly transformed by the introduction of Bruton tyrosine kinase and BCL‐2 inhibitors. Despite improved survival outcomes, treatment selection remains complex, particularly in older patients with comorbidities, frailty, and increased infectious vulnerability.
Enrica Antonia Martino +22 more
wiley +1 more source
Auer Rod-Like Inclusions in Chronic Lymphocytic Leukemia: A Case Report. [PDF]
Zhang T, Xie L.
europepmc +1 more source

